Usually ADAMTS13 activity is not decreased during acute phase of inflammation but majority of patients with COVID-19 were presenting lower ADAMTS13 activity, which may be explained by underlying endothelial cell injury [27]. This evidence concerns the gene ADAMTS13 and COVID-19.